DRASTOP SOLUTION IN OIL 100MG/ML AMPOULE 2ML

$35.10
No tax

DRASTOP SOLUTION IN OIL 100MG/ML AMPOULE 2ML -10pcs

Quantity

 

Security policy (edit with Customer reassurance module)

 

Delivery policy (edit with Customer reassurance module)

 

Return policy (edit with Customer reassurance module)

Composition

1 ml of the preparation contains:

active ingredient - Chondroitin sodium sulfate - 100 mg;

excipients - benzyl alcohol - 12 mg, 1% solution of sodium hydroxide or 0.1 M solution of hydrochloric acid - to pH 6.5 - 6.8, water for injection - up to 1 ml.

Pharmacodynamics

It has chondrostimulating, regenerating, anti-inflammatory and analgesic effects. Chondroitin sulfate is involved in the construction of the main substance of cartilage and bone tissue. Possesses chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, subchondrial bone; inhibits enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of chondrocyte proteoglycans. Helps reduce the release of inflammatory mediators and pain factors into synovial fluid, inhibits the secretion of leukotrienes and prostaglandins. It slows down bone resorption and reduces Calcium loss, accelerates bone repair processes. Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis.

It contributes to the restoration of the articular sac and the cartilaginous surfaces of the joints, prevents the collapse of the connective tissue, normalizes the production of the articular fluid.The use of the drug reduces pain and improves the mobility of the affected joints, while the therapeutic effect lasts a long time after the end of the course of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed after 2-3 weeks from the start of the course. Possessing structural similarity with Heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondrial microvasculature.

Pharmacokinetics

After i / m administration of chondroitin sodium sulfate is easily absorbed. Within 30 minutes after the injection, it is detected in the blood in significant concentrations. The maximum concentration of chondroitin sodium sulfate in plasma is reached after 1 hour, then gradually decreases over 2 days. Chondroitin sodium sulfate accumulates mainly in the cartilage tissue forming the joints. The synovium is not an obstacle to the penetration of the drug into the joint cavity. 15 minutes after the intramuscular injection of chondroitin, sodium sulfate is found in the synovial fluid, then penetrates into the articular cartilage, where its maximum concentration is reached after 48 hours

Indications and usage

Degenerative-dystrophic diseases of the joints and spine:

- Osteoarthritis of the peripheral joints;

- intervertebral osteoarthrosis and osteochondrosis.

Contraindications

- hypersensitivity to the drug;

- bleeding, bleeding tendency;

- thrombophlebitis;

- children's age (efficiency and safety are not established)

Adverse reactions

Allergic reactions (pruritus, erythema, urticaria, dermatitis), pain and hemorrhages at the injection site, dyspepsia, angioedema.

Perhaps increasing the effect of indirect anticoagulants, antiplatelet agents, fibrinolitikov, which requires more frequent monitoring of blood coagulation when used together.

The drug is administered i / m to 1 ml (100 mg of chondroitin sodium sulfate) every other day. With good portability, increase the dose to 2 ml (200 mg of chondroitin sodium sulfate), starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, repeated courses of treatment are possible after 6 months.

Overdosage

Overdose is not described and is unlikely.

Pregnancy and Breastfeeding

It is not recommended to use the drug during pregnancy. During treatment, breastfeeding should be discontinued due to lack of data.

Special notes

To achieve a stable clinical effect, at least 25 injections of the drug are necessary. The effect persists for several months after the end of treatment. To prevent exacerbations apply repeated courses of treatment. In case of allergic reactions or hemorrhages, treatment should be discontinued.

The impact on the ability to drive vehicles, mechanisms DRASTOP does not affect the ability to drive vehicles and engage in potentially hazardous activities that require increased attention.

Transparent, slightly yellowish solution

Storage conditions

Store at a temperature not higher than 25 ° С. Keep out of the reach of children

29 Items